SciBX: Science-Business eXchange Contents: January 12 2012, Volume 5 / Issue 2

TABLE OF CONTENTS January 12 2012, Volume 5 / Issue 2 Analysis Cover Story Translational Notes Targets and Mechanisms Tools The Distillery: Therapeutics Autoimmune disease Cancer Hepatic disease Infectious disease Inflammation Musculoskeletal disease Neurology The Distillery: Techniques Disease models Drug delivery Drug platforms Recommend to your library Web feed Available online only Subscribe Advertisement SciBX: Science-Business eXchange Recommend SciBX to your library today SciBx is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Subscribe to SciBX and you won't miss the next big thing. For more information visit: www.nature.com/scibx.   Trade Secrets A Nature Network blog by BIOENTREPRENEUR Brought to you by Nature Biotechnology Access the insights, advice and commentary from scientists and entrepreneurs building biotech sectors around the world. Join the global dialogue on life science entrepreneurship: http://blogs.nature.com/trade_secrets   Analysis Cover Story Top VCAM-1 engine drives bone metastases Michael J. Haas doi:10.1038/scibx.2012.30 A team led by Princeton researchers has shown that inhibiting vascular cell adhesion molecule-1/integrin α4 signaling could prevent bone metastases of breast cancer, thus handing companies with integrin α4 inhibitors on the market or in the clinic a potential repurposing opportunity. Full Text | PDF Translational Notes Top A conversation with Laurie Glimcher Joanne Kotz doi:10.1038/scibx.2012.31 As Laurie Glimcher was preparing to take over as dean of Weill Cornell, SciBX caught up with her to discuss research priorities for academic medical centers, the most effective models for promoting industry–academic partnerships and the potential for NYC to emerge as a biopharma hub. Full Text | PDF Targets and Mechanisms Top EETing away at metastasis Tim Fulmer doi:10.1038/scibx.2012.32 U.S. researchers have shown that antagonizing epoxyeicosatrienoic acids reduces tumor growth and metastasis in mice. The challenge will be finding a dosage that has the desired effect without impairing the function of the cardiovascular system. Full Text | PDF Tools Top Trypping up tumors Tracey Baas doi:10.1038/scibx.2012.33 Brazilian and U.S. researchers have engineered a prototype cancer immunotherapy consisting of an attenuated strain of Trypanosoma cruzi expressing a cancer antigen that stimulates a potent response in mice. The team is now tweaking the platform to ensure its safety. Full Text | PDF Distillery: Therapeutics Autoimmune disease Top Cystathionine β-synthase (CBS); cystathionase (CTH) doi:10.1038/scibx.2012.34 Cell culture studies suggest blocking hydrogen sulfide (H2S) signaling could help treat IBD. Full Text | PDF Cancer Top Guanylate binding protein 1 interferon-inducible (GBP1) doi:10.1038/scibx.2012.35 In vitro and mouse studies suggest inhibiting GBP1 could help treat glioblastoma. Full Text | PDF Focal adhesion kinase (FAK) doi:10.1038/scibx.2012.36 Cell culture studies suggest combining FAK and autophagy inhibitors could help treat cancer. Full Text | PDF IL-10 doi:10.1038/scibx.2012.37 Mouse studies suggest IL-10 could help treat cancer. Full Text | PDF Periostin (POSTN) doi:10.1038/scibx.2012.38 Mouse studies suggest inhibiting POSTN could help treat metastatic cancer. Full Text | PDF CXC chemokine receptor 4 (CXCR4; NPY3R) doi:10.1038/scibx.2012.39 In vitro and mouse studies identified cell-penetrating inhibitors of CXCR4 that could help treat hematologic malignancies. Full Text | PDF β-Catenin (CTNNB1) doi:10.1038/scibx.2012.40 Studies in mice suggest inhibiting CTNNB1 signaling could help treat melanoma. Full Text | PDF MAP kinase kinase 1 (MAP2K1; MEK1); MAP2K2 (MEK2) doi:10.1038/scibx.2012.41 Patient and cell culture studies identified mutations in MEK1 and MEK2 that could help guide treatment of patients with melanoma. Full Text | PDF Epoxyeicosatrienoic acids (EETs) doi:10.1038/scibx.2012.42 Mouse studies suggest antagonizing EETs could help treat solid cancers. Full Text | PDF Hepatic disease Top Serotonin (5-HT2B) receptor doi:10.1038/scibx.2012.43 Studies in mice suggest 5-HT2B antagonists could help treat liver fibrosis. Full Text | PDF Infectious disease Top Not applicable doi:10.1038/scibx.2012.44 Rodent and in vitro studies identified fluorocyclines that could help treat bacterial infections. Full Text | PDF HCV NS5B polymerase doi:10.1038/scibx.2012.45 In vitro and animal studies identified indole-based NS5B polymerase inhibitors that could treat HCV infection. Full Text | PDF Aryl hydrocarbon receptor (AHR) doi:10.1038/scibx.2012.46 Mouse studies suggest activating AHR could help decrease the severity of ocular HSV infection. Full Text | PDF Endoplasmic reticulum to nucleus signaling 1 (ERN1; IRE1) doi:10.1038/scibx.2012.47 In vitro studies suggest inhibiting IRE1 signaling could help treat influenza infection. Full Text | PDF P. falciparum cytochrome b (CYTB) doi:10.1038/scibx.2012.48 In vitro studies identified CYTB inhibitors that could help treat malaria. Full Text | PDF Inflammation Top Nuclear receptor subfamily 1 group D member 1 (NR1D1; REV-ERBAα) doi:10.1038/scibx.2012.49 Cell culture and mouse studies suggest agonizing the circadian regulator NR1D1 could help treat inflammatory diseases. Full Text | PDF Musculoskeletal disease Top Sialic acid doi:10.1038/scibx.2012.50 Mouse studies suggest increasing sialic acid levels with peracetylated N-acetylmannosamine could help treat hereditary inclusion body myopathy (HIBM). Full Text | PDF Neurology Top Apolipoprotein E (APOE) doi:10.1038/scibx.2012.51 A study in mice suggests antagonizing APOE could help treat AD. Full Text | PDF RASD family member 2 (RASD2; Rhes; TEM2); mammalian target of rapamycin (mTOR; FRAP; RAFT1) doi:10.1038/scibx.2012.52 In vitro and mouse studies suggest inhibiting Rhes could help prevent dyskinesia during PD therapy. Full Text | PDF Distillery: Techniques Disease models Top Mouse model of solute carrier family 29 member 3 (SLC29A3; ENT3)-associated lysosomal storage disorders doi:10.1038/scibx.2012.53 Ent3 knockout mice could be used as a model to help develop new treatments for lysosomal storage disorders. Full Text | PDF Rat model of TAR DNA binding protein 43 (TDP-43; TARDBP)-driven amyotrophic lateral sclerosis (ALS) doi:10.1038/scibx.2012.54 Rats engineered to express an ALS-associated mutant form of TDP-43 could be used to identify new treatments for the disease. Full Text | PDF Drug delivery Top Dextran-based hydrogel scaffold for burn wound skin regeneration doi:10.1038/scibx.2012.55 Mouse studies suggest dextran-based hydrogels could be used as scaffolds to improve burn wound healing. Full Text | PDF Drug platforms Top Crystal structure of a Fab fragment in complex with MAC-1 (CD11b-CD18) doi:10.1038/scibx.2012.56 The crystal structure of a Fab bound to the integrin A domain of MAC-1 could aid the design of integrin antagonists with improved safety profiles. Full Text | PDF Ebola glycoprotein (GP1)-based vaccine to prevent Ebola infection doi:10.1038/scibx.2012.57 An in vitro and mouse study suggests a vaccine based on a GP1 fusion protein could help protect against Ebola infection. Full Text | PDF Tobacco-manufactured antibodies to treat Ebola infection doi:10.1038/scibx.2012.58 A study in mice suggests tobacco-manufactured mAbs could help prevent Ebola infection. Full Text | PDF You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.